Health Care·Biotechnology·$185.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.05 | N/A | -5.66% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $1.05 | N/A | -5.66% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Overall, management expressed concerns about market conditions impacting performance. They are prioritizing cost control measures.
Management noted challenges in the current market environment.
They emphasized a focus on cost management and operational efficiency.
Amgen's earnings report indicates some struggles, particularly reflected in the EPS miss. The stock's decline of 1.57% suggests investor concern over the company's current performance and market challenges. Without guidance, investors may remain cautious about future prospects.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AIR PRODS & CHEMS IN
Jan 22, 2010